BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Biologics

Neurimmune And Alexion Expand Global Collaboration To Advance NI009 For Light Chain Amyloidosis

Neurimmune announced that it has expanded on its transthyretin amyloid cardiomyopathy (ATTR-CM) collaboration with Alexion, AstraZeneca Rare Disease ...

December 05, 2025 | News

AGC Biologics Strengthens Global Cell Line Capabilities With ATUM Partnership and Leap In Technology

New offering provides drug developers with flexible and powerful cell line development options for monoclonal antibodies, multi-specific and complex mole...

December 04, 2025 | News

Ajinomoto CELLiST Korea Launches New CELLiST AAV Production Supplement 1 to Boost Viral Vector Productivity

Ajinomoto Co in Tokyo collaborated with its United States based consolidated subsidiary Forge Biologics, a leading CDMO in adeno associated virus developme...

December 04, 2025 | News

Amaran Biotech Achieves FDA Acknowledgement for Type II DMF of AB801 Vaccine Adjuvant

Amaran Biotech, a next-generation Contract Development and Manufacturing Organization (CDMO), announced that its self-developed, GMP-grade high-purity vacc...

December 03, 2025 | News

Imugene and JW Therapeutics Launch First-in-Class “Mark and Kill” Solid Tumor Collaboration

Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytic...

December 01, 2025 | News

Juventas’ CAR-T Therapy Ina-cel Receives NMPA Approval for Large B-Cell Lymphoma

Juventas Cell Therapy Co., Ltd. (hereinafter referred to as "Juventas") announced that its independently developed CAR-T cell therapy product, Inatica...

December 01, 2025 | News

BioDlink Drives Global Biologics Innovation with World’s First Approved EGFR-Targeted ADC

Recognized as Biologics CDMO of the Year, BioDlink shares insights into the world's first approved EGFR-targeted ADC for recurrent/metastatic nasopharyng...

December 01, 2025 | News

IASO Bio Achieves Landmark Hong Kong Approval for Fucaso CAR-T Therapy

IASO Biotechnology ("IASO Bio"), a commercial-stage biopharmaceutical company dedicated to the discovery, development, manufacturing, and commerciali...

November 28, 2025 | Regulatory

Teijin Pharma to Receive $5M Milestone as Bioprojet Advances Novel Narcolepsy Candidate to Phase 1

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, announced that it will receive in Q4 2025 a milestone paym...

November 28, 2025 | News

Zydus and RK Pharma Partner on Innovative Sterile Injectable for Oncology Supportive Care

Zydus Lifesciences Ltd. (including its subsidiaries and affiliates), a global innovation-driven healthcare company, announced that it has entered into an e...

November 27, 2025 | News

mAIbe and LenioBio Form Strategic Partnership to Accelerate Next-Gen Antibody Discovery

mAIbe and LenioBio are pleased to announce a new strategic collaboration aimed at accelerating the discovery and experimental validation of next-generation...

November 27, 2025 | News

eXmoor Pharma and Royal Free London’s CVIC Form Strategic Partnership to Streamline UK Cell and Gene Therapy Manufacturing

eXmoor Pharma, the integrated cell and gene therapy CDMO with embedded consultancy expertise, and Royal Free London NHS Foundation Trust, throug...

November 27, 2025 | News

Mabwell Doses First Patient in Phase One Two Study of Novel CDH17 Targeting ADC 7MW4911 for Advanced Solid Tumours

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed...

November 26, 2025 | News

Innova Therapeutics Acquires Enci Therapeutics To Advance First in Class SFRP2 Antibody IVT8086 for Solid and Haematological Cancers

The acquisition of Enci Therapeutics will advance Innova Therapeutics' lead program, IVT-8086, a humanized monoclonal antibody targeting SFRP2 which is exp...

November 26, 2025 | News

Stay Connected